首页> 外文OA文献 >PMU59 - ARE THERE ANY IMPLICIT GUIDELINES FOR INCLUDING ADVERSE EVENTS IN COST-EFFECTIVENESS MODELS INTENDED FOR FRENCH HEALTH AUTHORITIES? AN ANALYSIS OF EFFICIENCY OPINIONS

【2h】

PMU59 - ARE THERE ANY IMPLICIT GUIDELINES FOR INCLUDING ADVERSE EVENTS IN COST-EFFECTIVENESS MODELS INTENDED FOR FRENCH HEALTH AUTHORITIES? AN ANALYSIS OF EFFICIENCY OPINIONS

机译：PMU59 - 是否有任何隐含的指导方针，包括用于法国卫生当局的成本效益模型的不良事件？效率意见分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
M Caillon; C. Cartier-Bechu; S Roze;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. An implicit opinion analysis model based on feature-based implicit opinion patterns [J] . Fang Zhao, Zhang Qiang, Tang Xiaoan, Artificial Intelligence Review: An International Science and Engineering Journal . 2020,第6期

机译：基于特征的隐含意见模式的隐含意见分析模型
2. Recommendations for using TNFα antagonists and French Clinical Practice Guidelines endorsed by the French National Authority for Health [J] . Go?bV., ArdizzoneM., ArnaudL., Joint, bone, spine : . 2013,第6期

机译：使用TNFα拮抗剂的建议和法国国家卫生局认可的法国临床实践指南
3. 1) VALUE OF THE CLINICAL DECISION SUPPORT SYSTEM FOR ADVERSE DRUG EVENT PREVENTION: A COST-EFFECTIVENESS ANALYSIS AND COST-BENEFIT ANALYSIS [J] . Kim H. T., Lee S., Suh H. S. Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2016,第7期

机译：1）预防药物不良事件的临床决策支持系统的价值：成本效益分析和成本效益分析
4. On Modeling Risk of Adverse Events In Complex Healthcare Settings [C] . Reza Kazemi, Ali Mosleh, Meghan Dierks SAM10 . 2012

机译：复杂医疗环境中不良事件的风险建模
5. Modeling Health Preferences and Cost-Effectiveness of Current Breast Cancer Screening Technologies to Inform Policy, Practice, and Prevention Strategies. [D] . Decker-Palmer, Marquita. 2017

机译：对当前的乳腺癌筛查技术的健康偏好和成本效果进行建模，以告知政策，实践和预防策略。
6. Bayesian analysis of trial-based cost-effectiveness in the presence of missing data: effects of including covariates on efficiency of estimation in the ASTER trial [O] . Linda Sharples, Christopher Jackson, Ella Wheaton, 2011

机译：在缺少数据的情况下基于试验的成本效益的贝叶斯分析：在ASTER试验中包括协变量对估计效率的影响
7. PRM112 - INCORPORATION OF ANTI-CANCER DRUGS ADVERSE EVENTS IN HEALTH ECONOMIC OPINIONS OF THE FRENCH NATIONAL AUTHORITY FOR HEALTH (HAS) [O] . S Branchoux, F Cotte 2018

机译：PRM112 - 法国国家权威卫生经济意见的抗癌药物的不良事件（有）

PMU59 - ARE THERE ANY IMPLICIT GUIDELINES FOR INCLUDING ADVERSE EVENTS IN COST-EFFECTIVENESS MODELS INTENDED FOR FRENCH HEALTH AUTHORITIES? AN ANALYSIS OF EFFICIENCY OPINIONS

著录项

相似文献

相关主题

期刊订阅